
- Pharmaceutical Commerce - January/February 2009
CVS Caremark settles with FTC and HHS over patient-privacy issues
Alleged mishandling of discarded patient records call the giant retailer’s privacy safeguards into question
The data-focused CVS Caremark Corp. (Woonsocket, RI) has made an involuntary $2.25 million investment in protecting customer information and has fortified its procedures for handling retail trash. The investment takes the form of a fine from the Department of Health and Human Services, part of a two-pronged settlement in which the company agreed to implement appropriate procedures for handling personal information about customers and employees in response to an FTC complaint, and agreed to pay the fine and implement a corrective action plan for Health Insurance Portability and Accountability Act of 1996 (HIPAA) privacy rule compliance to settle with HHS.
"Through the settlement we are required to maintain our security policies and our employee training around them, and we are subject to inspections,” says Mike DeAngelis, CVS Caremark spokesman. Both matters stem from 2006 press reports alleging that patient information maintained by the pharmacy was being disposed of in unsecured industrial trash containers. According to FTC documents, “CVS Caremark made claims such as ‘CVS/pharmacy wants you to know that nothing is more central to our operations than maintaining the privacy of your health information,’” which FTC alleged was a deceptive claim.
HHS and FTC will also require CVS Caremark to actively monitor its compliance with the agreements. The company must hire a third party to assess CVS Caremark compliance and report to the federal agencies. The HHS corrective action plan will be in place for three years; the FTC requires monitoring for 20 years.
As a combination of one of the largest drugstore chains and one of the largest PBMs, CVS Caremark has big plans for becoming more central to healthcare IT specifically, and overall healthcare generally. In a recent BusinessWeek interview, CVS Caremark CEO Tom Ryan detailed the key role of customer data in the company’s strategy to grow while simultaneously helping to rein in healthcare costs through increased health monitoring and patient compliance, among other activities. Ryan said in the interview that the company’s customer data reveals when a customer has stopped taking medication. For PBM patients, that may prompt a telephone reminder from the store for the customer to get a refill.
Articles in this issue
over 16 years ago
Closing The Circle On Patient Adherenceover 16 years ago
3PLs Rise in Forward-Thinking Supply Chain Modelsover 16 years ago
A Pitched Battle in Cardiovascular Drug Marketingover 16 years ago
Wyeth Loses Supreme Court Case Over 'Implied' Pre-Emptionover 16 years ago
Syringe Design Gets a Makeoverover 16 years ago
Refinements in Cold Chain Secondary Packagingover 16 years ago
Inmar Rebrands Reverse-Logistics and Related Business Unitsover 16 years ago
The Packaging Contribution to Patient Adherenceover 16 years ago
Moving the Dial on Patient AdherenceNewsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.





